FindTrial
Sign In

Construction of Risk Prediction Model for Bone Metastasis of Prostate Cancer based on TAMs/CCL5

Risk Prediction of Bone Metastasis of Prostate Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063111
Enrollment
Unknown
Registered
2022-08-31
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Bone-metastasis group:None
Group of patients without bone metastasis:None

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Biopsy pathology meets the diagnostic criteria for prostate cancer; 2. Radiographically confirmed patients with or without bone metastasis; 3. The accuracy of traditional Chinese medicine.

Exclusion criteria

Exclusion criteria: 1. Other urinary system diseases and other serious heart, liver and kidney diseases, including secondary primary tumors in addition to prostate cancer. 2. Patients who meet the diagnosis of prostate cancer but belong to metastases other than bone metastases. 3. Patients who do not receive treatment according to regulations or have incomplete data.

Design outcomes

Primary

MeasureTime frame
Chemokine ligand 5(CCL5);—

Countries

China

Contacts

Public ContactXiang Songtao

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

tonyxst@gzucm.edu.cn+86 13711515862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026